Research Programs

Biography

Research Interests

Multiple sclerosis (MS), MRI biomarkers with clinical utility in prognostication and disease monitoring, cohort studies

Research Activities

Jiwon Oh is a staff neurologist, scientist, and Medical Director of the Barlo Multiple Sclerosis (MS) Program at St. Michael’s Hospital, University of Toronto. Dr. Oh’s research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She leads the MRI research program at St. Michael’s Hospital, and is the principal investigator on numerous local and multi-center collaborative studies, including the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), which is a national prospective cohort study designed to better understand progression in MS.

Recent Publications

  1. Chen, L, Ren, Z, Clark, KA, Lou, C, Liu, F, Cao, Q et al.. Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis. J Neuroimaging. 2024; :. doi: 10.1111/jon.13242. PubMed PMID:39410780 .
  2. Kalia, LV, Asis, A, Arbour, N, Bar-Or, A, Bove, R, Di Luca, DG et al.. Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. Nat Rev Neurol. 2024; :. doi: 10.1038/s41582-024-01023-0. PubMed PMID:39375563 .
  3. Manning, AR, Letchuman, V, Martin, ML, Gombos, E, Roberts-Fitzgerald, T, Cao, Q et al.. Multicenter automated central vein sign detection performs as well as manual assessment for the diagnosis of multiple sclerosis. AJNR Am J Neuroradiol. 2024; :. doi: 10.3174/ajnr.A8510. PubMed PMID:39332906 .
  4. Oh, J, Arbour, N, Giuliani, F, Guenette, M, Kolind, S, Lynd, L et al.. The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics. Ther Adv Neurol Disord. 2024;17 :17562864241273045. doi: 10.1177/17562864241273045. PubMed PMID:39282637 PubMed Central PMC11402083.
  5. Toljan, K, Daboul, L, Raza, P, Martin, ML, Cao, Q, O'Donnell, CM et al.. Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis. Mult Scler. 2024;30 (10):1268-1277. doi: 10.1177/13524585241271988. PubMed PMID:39234802 PubMed Central PMC11421977.
  6. Kuczynski, AM, Jones, A, Kimbrough, D, Muccilli, A, Roy-Hewitson, C, Okuda, DT et al.. Clinical characteristics and disease burden of African, Caribbean, and Black people with multiple sclerosis in Toronto, Canada. Mult Scler Relat Disord. 2024;90 :105802. doi: 10.1016/j.msard.2024.105802. PubMed PMID:39126938 .
  7. Roos, I, Sharmin, S, Malpas, C, Ozakbas, S, Lechner-Scott, J, Hodgkinson, S et al.. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Mult Scler. 2024;30 (9):1163-1175. doi: 10.1177/13524585241267211. PubMed PMID:39087208 .
  8. De Brouwer, E, Becker, T, Werthen-Brabants, L, Dewulf, P, Iliadis, D, Dekeyser, C et al.. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study. PLOS Digit Health. 2024;3 (7):e0000533. doi: 10.1371/journal.pdig.0000533. PubMed PMID:39052668 PubMed Central PMC11271865.
  9. Scalfari, A, Traboulsee, A, Oh, J, Airas, L, Bittner, S, Calabrese, M et al.. Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions. Ann Neurol. 2024; :. doi: 10.1002/ana.27034. PubMed PMID:39051525 .
  10. Martin, SJ, Guenette, M, Oh, J. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy. Drug Des Devel Ther. 2024;18 :3025-3042. doi: 10.2147/DDDT.S388410. PubMed PMID:39050801 PubMed Central PMC11268567.
Search PubMed

Affiliations & Other Activities

  • Staff Neurologist, Division of Neurology, Department of Medicine, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto
  • Adjunct Faculty, Department of Neurology, Johns Hopkins University